.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
AstraZeneca
Teva
Johnson and Johnson
Citi
Medtronic
Fuji
Farmers Insurance
Boehringer Ingelheim
Daiichi Sankyo

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Treatment of protein degradation disorders
Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
Inventor(s): Anderson; Kenneth C. (Wellesley, MA), Bradner; James E. (Weston, MA), Greenberg; Edward Franklin (Cleveland, OH), Hideshima; Teru (Brookline, MA), Kwiatkowski; Nicholas Paul (Auburn, MA), Mazitschek; Ralph (Belmont, MA), Schreiber; Stuart L. (Boston, MA), Shaw; Jared (Davis, CA), Haggarty; Stephen J. (Gloucester, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA) Dana-Farber Cancer Institute, Inc. (Boston, MA)
Application Number:14/679,800
Patent Claims:1. A method of treating a subject suffering from a solid tumor comprising administering to the subject a therapeutically effective amount of a proteasome inhibitor and an aggresome inhibitor, wherein the aggresome inhibitor selectively inhibits HDAC6.

2. The method of claim 1, wherein the solid tumor is a breast, lung, liver, colon or prostate solid tumor.

3. The method of claim 1, wherein the proteasome inhibitor is selected from the group consisting of bortezomib, MG132, sapojargon, and NPI-0052.

4. The method of claim 1, wherein the aggresome inhibitor is of the formula: ##STR00074## or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; --OR.sub.A; --C(.dbd.O)R.sub.A; --CO.sub.2R.sub.A; --SR.sub.A; --SOR.sub.A; --SO.sub.2R.sub.A; --N(R.sub.A).sub.2; --NHC(O)R.sub.A; or --C(R.sub.A).sub.3; wherein each occurrence of R.sub.B is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety; R.sub.2 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstitued aryl; substituted or unsubstituted heteroaryl; --OR.sub.B; --C(.dbd.O)R.sub.B; --CO.sub.2R.sub.B; --CN; --SCN; --SR.sub.B; --SOR.sub.B; --SO.sub.2R.sub.B; --NO.sub.2; --N(R.sub.B).sub.2; --NHC(O)R.sub.B; or --C(R.sub.B).sub.3; wherein each occurrence of R.sub.B is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety; and R.sub.3 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstitued aryl; substituted or unsubstituted heteroaryl; --OR.sub.C; --C(.dbd.O)R.sub.C; --CO.sub.2R.sub.C; --CN; --SCN; --SR.sub.C; --SOR.sub.C; --SO.sub.2R.sub.C; --NO.sub.2; --N(R.sub.C).sub.2; --NHC(O)R.sub.C; or --C(R.sub.C).sub.3; wherein each occurrence of R.sub.C is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety.

5. The method of claim 1, wherein the aggresome inhibitor is of the formula: ##STR00075## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is hydrogen, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; n is 1-5; R.sup.2 is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; X is --O--, --C(R.sup.2A).sub.2--, --S--, or --NR.sup.2A--, wherein R.sup.2A is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; or wherein two or more occurrences of R.sup.2 and R.sup.2A, taken together, form an alicyclic or heterocyclic moiety, or an aryl or heteroaryl moiety; R.sup.3 is an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; and Y is hydrogen or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety.

6. The method of claim 1, wherein the aggresome inhibitor is selected from the group consisting of: ##STR00076## ##STR00077## and pharmaceutically acceptable salts thereof.

7. The method of claim 1, wherein the aggresome inhibitor is the following: ##STR00078## or a pharmaceutically acceptable salt thereof.

8. The method of claim 1, wherein the aggresome inhibitor is of the following formula: ##STR00079## or a pharmaceutically acceptable salt thereof, wherein: each X is independently O, S, CH.sub.2, or NR.sub.3; Y is O, S, CH.sub.2, or NR.sub.4; Ar.sub.1 and Ar.sub.2 are each independently an aryl group; R.sub.1 is a lower alkyl group or an aryl group; R.sub.2 is hydrogen, a lower alkyl group or an aryl group; and R.sub.3 is hydrogen, a lower alkyl group, an aryl group, an alkylcarbonyl, an alkoxycarbonyl group, or an aminocarbonyl group.

9. The method of claim 8, wherein: X is for both occurrences O; Y is S; Ar.sub.1 is phenyl or substituted phenyl; Ar.sub.2 is heteroaryl; R.sub.1 is phenyl or substituted phenyl; and R.sub.2 is hydrogen.

10. The method of claim 1, wherein the aggresome inhibitor inhibits the C-terminal aceylation activity of HDAC6, thereby inhibiting aggresome mediated protein degradation.

11. The method of claim 1, wherein the aggresome inhibitor is dyenin.

12. The method of claim 1, further comprising obtaining a biological sample from a subject.

13. The method of claim 1, further comprising administering a therapeutically effective amount of one or more additional protein degradation inhibitors to the subject.

14. The method of claim 13, wherein at least one of the additional protein degradation inhibitors is an aggresome inhibitor.

15. The method of claim 13, wherein at least one of the additional protein degradation inhibitors is a proteasome inhibitor.

16. The method of claim 1, further comprising monitoring the treatment or progress of the subject.

17. The method of claim 1 further comprising co-administering one or more of a chemotherapeutic agent, radiation agent, hormonal agent, biological agent, or an anti-nflammatory agent to the subject.

18. The method of claim 17, wherein the chemotherapeutic agent is tamoxifen, trastuzamab, raloxifene, doxorubicin, fluorouracil/5-fu, pamidronate disodium, anastrozole, exemestane, cyclophosphamide, epirubicin, letrozole, toremifene, fulvestrant, fluoxymesterone, trastuzumab, methotrexate, megastrol acetate, docetaxel, paclitaxel, testolactone, aziridine, vinblastine, capecitabine, goselerin acetate, zoledronic acid, taxol, or vincristine.

19. The method of claim 8, wherein: X is for both occurrences O; Y is S; Ar.sub.1 is phenyl or substituted phenyl; Ar.sub.2 is optionally substituted oxazolyl; R.sub.1 is 4-aminosubstituted phenyl; and R.sub.2 is hydrogen.

20. The method of claim 1, wherein the subject is a human.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe President and Fellows of Harvard College (Cambridge, MA) Dana-Farber Cancer Institute, Inc. (Boston, MA) Anderson; Kenneth C. (Wellesley, MA), Bradner; James E. (Weston, MA), Greenberg; Edward Franklin (Cleveland, OH), Hideshima; Teru (Brookline, MA), Kwiatkowski; Nicholas Paul (Auburn, MA), Mazitschek; Ralph (Belmont, MA), Schreiber; Stuart L. (Boston, MA), Shaw; Jared (Davis, CA), Haggarty; Stephen J. (Gloucester, MA) ► SubscribeRXOrphansearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Australia2006226861Aug 16, 2012
Australia2006226861Sep 28, 2006
Canada2601706Sep 20, 2016
Canada2601706Sep 28, 2006
Canada2937005Sep 28, 2006
China101495116Jul 29, 2009
European Patent Office1861126Dec 05, 2007
European Patent Office1861126Nov 18, 2009
European Patent Office2491926Aug 29, 2012
Japan2009509910Mar 12, 2009
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Teva
QuintilesIMS
Daiichi Sankyo
Johnson and Johnson
Julphar
UBS
Novartis
Citi
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot